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Cyclin-dependent kinases (CDKs) serve as target for various cancers including skin cancer. 
Secoisolariciresinoldiglucoside (SDG) and lignans exert anticancer effect on colon cancer through inhibition of CDKs. 
However, reports of SDG lignan concentrate (SLC) of Linum usitatissimum (L.) on skin cancer are not available. Hence, in 
this study, we evaluated the effect of SLC of L. usitatissimum on skin cancer, and determined the mechanism of action. Cell 
viability studies were done using the A-375 cell line. Skin cancer was induced by dimethyl Benz(a) anthracene and croton 
oil in female balb/c mice. SLC (5%) was administered from the 7th to 16th week after which we evaluated serum and tissue 
parameters. The IC50 value of SLC was found to be 93.7 µg/mL on the A-375 cell line. Skin cancer control animals 
exhibited increased tumor volume and burden and an increase in non-specific serum markers and tissue markers. Treatment 
with SLC decreased tumor volume and burden, and serum and tissue markers. Histopathological studies also depicted 
protection with SLC treatment. Docking studies revealed that SDG exhibits a good binding score with CDK4. Skin cancer 
control mice showed significantly increased CDK4 mRNA and decreased p53 mRNA levels which were prevented by SLC 
treatment. SLC exhibited a chemopreventive effect in skin cancer depicted by a reduction in serum biomarker, oxidative 
stress, collagen levels, tumor volume, tumor burden, and histopathological studies. These effects are mediated through the 
inhibition of CDK4 and upregulation of p53. 
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Secoisolariciresinoldiglucoside 
Non-melanoma skin cancer affects 1.2 million people 
worldwide, about 0.064 million succumbed to this 
disorder in 2020
1
. Different therapies are used for 
treating skin cancer viz., surgical treatments, 
chemotherapy, radiation therapy, and photodynamic 
therapy. However, the occurrence of different side 
effects, recurrence of diseases, and effectiveness 
against only early stages of skin cancer are certain 
limitations with current therapies. These drawbacks 
emphasize the need for newer molecules acting  
on novel targets of skin diseases
2
. Cyclins  
and cyclin-dependent kinases (CDKs) are one such 
target. 
 
Cyclins and CDKs are regulatory molecules 
governing the multiplication of the cells. CDK4 
along with cyclin D causes activation and hyper-
phosphorylation of regulatory protein retinoblastoma 
(Rb) resulting in activation of transcriptional 
regulators which transcribe different proteins 
required for cell division
3
. Blocking the action of 
CDK4 stops the DNA duplication for cell 
multiplicity resulting in a block in the cancer cell 
growth. p53 is a tumor suppressor transcription 
factor, and loss of one or two alleles of p53 has been 
shown to induce tumors
4
. p53 is also reported to 
inhibit Cdk4 activity through p21 and by repression 
of Cdk4 synthesis
5
. Thus, targeting these CDK4 and 
p53 can prove to be effective in cancer. Current 
CDK inhibitors have several limitations viz., non-
selective toxic effects like myelosuppression, 
thrombosis, skin rashes, and fatigue
6
. Such 
limitations point out towards discovery of novel 
molecules for the treatment of skin cancer.  
 
Amongst the plethora of herbal molecules, lignans 
are diphenolic compounds reported to inhibit cell 
growth by acting on CDKs
7
. Flaxseeds, obtained  
from Linum usitatissimum L. (L. usitatissimum), are  
a rich source of a specific lignan called 
secoisolariciresinoldiglucoside (SDG)
8
. Globally in 
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many parts of the world, flaxseed is cultivated for 
fibers and oil in addition to nutritive applications. 
Owing to the presence of alpha-linolenic acid, 
lignans, and dietary fiber, it is considered a functional 
food
9
. Flaxseed lignans are reported to have an 
anticancer effect against colon cancer, diabetic colon 
cancer and diabetes induced vascular reactivity
10-12
. 
Despite these, no reports of the effect of  
L. usitatissimum on skin cancer are not available. 
Hence, present study, are to study the effect of SDG 
lignan concentrate of L. usitatissimum on skin cancer 
and to determine its mechanism of action. 
 
Material and Methods 
 
Preparation of SDG lignan concentrate (SLC) 
Flaxseeds were obtained, identified, and 
authenticated by the Department of Pharmacognosy, 
Institute of Pharmacy, Nirma University, Ahmedabad, 
India. The coarse powder of the dried seeds was 
defatted using n-hexane followed by preparation of 
ethanolic extract using a soxhlet extractor. The SLC 




Quantitative analysis using chromatography 
The SDG standard was separated using preparative 
thin-layer chromatography (TLC). HPTLC was 
performed on a precoated silica gel HPTLC60 
(Merck), F 254 (5cm×10cm) for the quantification of 
SDG in SLC. The sample was sprayed with nitrogen 
gas on the HPTLC plates using Linomat 5. After 
application, the plates were developed in CAMAG 
horizontal development using a solvent system (ethyl 
acetate:methanol:water:formic acid - 7.7:1.3:1.0:0.5). 
Densitometric evaluation was performed with help 
of CAMAG TLC SCANNER 3 along with winCATS 
software (version 3.5). Scanning parameters were set 
in reflectance mode at 282 nm. 
 
In vitro cell viability studies 
A-375 cell culture was derived from National 
Centre for Cell Science (NCCS), Pune. Stock cells 
of these cell lines were cultured in Dulbecco's 
Modified Eagle's medium, low glucose with 
glutamine (DMEM), supplemented with 10% fetal 
bovine serum (FBS), 5% Hank's Balanced Salt 
Solution (HBSS), penicillin, streptomycin, and 
amphotericin–B, in a humidified atmosphere of  
5% CO2 at 37°C until confluence was reached.  






In vivo pharmacological studies 
 
Induction of skin cancer 
Female Balb/c mice weighing 25-30 g were chosen 
for the study and were maintained under controlled 
conditions viz., temperature at 25±2°C, and 
relative humidity at 55±5%. All the animals had 
access to standard laboratory mice chow and  
UV-filtered water ad libitum. The experimental 
protocol was approved by Institutional Animal Ethics 
Committee (Protocol number: IP/PCOL/MPH/13-
1/010 dated 08/08/2013). 
 
Animals were divided into eight groups: Normal 
control (CON), Control animals treated with 2% 5-FU 
solution(COF), Control animals treated with 5% 
suspension of SLC(COS5), Skin cancer control(SCC), 
Skin cancer treated with 2% 5-FU solution(SCF), 
Skin cancer treated with 5% suspension of 
SLC(SCS5). 2% 5-FU is the standard dose used for 
skin cancer and the dose of SLC at 5% was selected 
based on preliminary studies. 50 µL of the dimethyl 
benz (a) anthracene (DMBA) (1Mg/mL) solution was 
sprayed twice weekly for one week. About 1% croton 





 week. The drug treatment was started from the 
7
th
 week and continued till the 16
th
 week. About  
100 L of respective drugs were applied on the back 
region with help of a paint brush (size 1). Tumor 
volume and tumor burden were determined using the 
following formula: 




Tumor burden = Tumor volume × Number of tumors 
 
Analysis of parameters 
After 16 weeks, blood samples were collected, 
serum was separated and analyzed for gamma-
glutamyltransferase(GGT), lactic acid dehydrogenase 
(LDH), and C-reactive protein levels(CRP) 
spectrophotometrically (Shimadzu UV-1601, Japan) 
using available biochemical diagnostic kits (Labcare 
Diagnostics Pvt. Ltd., India)
15,16
. Following blood 
collection, all the animals were sacrificed, dorsal skin 
from the mice was carefully removed. The skin 
portion in which the tumor was developed was 





, and collagen 
levels
19,20
. The skin was also subjected to 
histopathological studies for hematoxylin and eosin 
(HE) staining. The sections were observed and 




photographed using Olympus (trinocular-CX21FS1) 
photomicroscope under 40X magnification. 
 
mRNA expression studies 
CDK4 and p53 mRNA levels were determined
14
. 
Briefly, 200-300 mg of skin specimen were taken and 
homogenized. Total ribonucleic acid (RNA) was 
extracted using FastRNA® Pro Green Kit (M.P. 
Biomedicals) following the instructions of the users-
manual. First-strand cDNA was synthesized from 1. 0 
µg of RNA using First Strand cDNA Synthesis Kit 
(Novagen) and incubated at 42°C for 60 min followed 
by 70°C for 10 min. PCR was carried out to check 
gene expression using primers specific for rat  
β actin (Forward: 5'-ATCCGTAAAGACCTCTATGC-3'; 
Reverse: 5'-AACGCAGCTCAGTAACAGTC-3'), 
CDK4 (Forward: 5'-CTTCCCGTCAGCACAGTTC-3'; 
Reverse: 5'-GGTCAGCATTTCCAGTAG C-3')  and 
p53 (Forward: 5'-GGGACAGCCAAGTCTGTTATG-3’; 
Reverse: 5'-GGAGTCTTCCAGTGTGATGAT-3') 
according to the user manual. The quantification of 
gene expression was done by Phroetix 1D v 
11.4:1DPRO-J3K9-RG5Z-AN (Total lab software) 
 
Docking Studies 
Sybyl × 1.3 was used for molecular docking
21
. The 
co-crystallized structure of CDK4 [PDB id: 2W96] 
was taken from Protein Data Bank (PDB) and 
modified for docking calculations. Co-crystallized 
ligand was removed from the structure, water 
molecules were removed, H atoms were added, and 
side chains were fixed during protein preparation. 
SDG and standards of CDK4 viz., purvanalol, 
roscovitine, and staurosporine were docked and the 




Results are presented as Mean ± SEM. Statistical 
differences between the means of the various groups 
were evaluated using one-way analysis of variance 
(ANOVA) followed by Tukey’s test. Data were 





The peak of SDG was obtained at 0.26 Rf, using 
the separated SDG as an internal standard. The 
standard curve was plotted and r
2
 value obtained was 
0.991 (Fig. 1A). Using the linearity equation it was 
found that 17.57 µg of SDG was present in 1Mg of 
SLC (Fig. 1B). 
 
Cell viability 
Fig. 2 represents the % cell inhibition of SLC and 
5-FU on A-375 cells. The IC 50 value of SLC was 
found to be 93.7 µg/mL, while that for 5-FU was 
89.9µg/mL. 
 
Tumor volume and Tumor burden 
The tumors started appearing from the 10
th
 week. 
There was a significant increase in tumor volume and 
tumor burden in the skin cancer control group from 
the 10
th
 to the 16
th
 week (Table 1). Treatment with 2% 
5-FU significantly reduced the tumor volume and 
burden from the 12
th
 week and continued reduction 
till the 16
th
 week. Treatment with 5% SLC 
significantly reduced the tumor volume and burden 
from the 14
th
 week and 12
th
 week respectively and 
continued reducing till the 16
th
 week (Table 1).  
 
 
Fig. 1 — (A) Calibration curves in linear in the range of 500, 700, 
900, 1000, 1100, 1300 and 1500 ng for SDG standard; and  
(B) HPTLC densitogram of SLC 
 






Fig. 2 — A375 cells were treated with various concentrations of 
SLC and 5-FU for 24 h. [Cell viability was measured using the 
MTT assay. The IC50 values of SLC and 5-FU were determined. 
Results shown are representative of three independent 
experiments] 
 
Table 1 — Effect of SLC on tumor burden and tumor volume 
No of week CON SCC SCF SCS5 
Tumor burden 
10th week 0.0±0 39.63±0.62* 36.02±0.47 24.60±0.41 
12th week 0.0±0 53.64±0.59* 27.95±0.32# 40.72±0.66# 
14th week 0.0±0 115.71±0.73* 15.52±0.32# 57.77±0.90# 
16th week 0.0±0 185.75±1.09* 7.91±0.1# 75.79±0.99# 
Tumor volume 
10th week 0.0±0 6.93±0.62* 7.20±0.47 5.62±0.41 
12th week 0.0±0 7.08±0.59* 5.58±0.32# 8.57±0.66 
14th week 0.0±0 12.65±0.73* 3.19±0.32# 10.27±0.90# 
16th week 0.0±0 23.21±1.09* 1.82±0.1# 14.10±0.99# 
[Values represent Mean ± SEM of 6 mice. * Significantly different 
from the Normal control group (P <0.05). #Significantly different 
from the skin cancer control group (P <0.05). CON, Normal 
control; SCC, Skin cancer control group; SCF, Skin cancer treated 
with 2% 5-Flurouracil;  SCS2, Skin cancer treated with 2% SLC; 
and SCS5, Skin cancer treated with 5% SLC] 
 
Non-specific serum markers 
At the end of 16
th
 week, there was a significant 
increase in the serum GGT, LDH, and CRP levels in 
the skin cancer control group as compared to normal 
control group. Treatment with 2% 5-FU and 5% SLC 
significantly reduced these levels in disease-treated 
groups as compared to the skin cancer control group 
(Table 2).  
 
Tissue markers 
DMBA and croton oil produced a significant 
increase in MDA and a significant decrease in SOD 
and GSH levels in skin tissue of skin cancer control 
groups as compared to the normal control group. 
Treatment with 2% 5-FU and 5% SLC significantly 
reduced the MDA levels and significantly increased 
the SOD and GSH levels in disease treated groups as 
compared to skin cancer control group (Table 2). 
There was a significant increase in tissue collagen 
levels in the skin cancer control group as compared to 
the normal control group. Treatment with 2% 5-FU 
and 5% SLC significantly reduced the tissue collagen 
levels in disease-treated groups as compared to the 
skin cancer control group (Table 2). 
 
Histopathological studies 
Histopathological analysis of skin tissues from 
control mice depicted well distribution of the 
epidermis, dermis and subcutis layers; the presence of 
normal sebaceous glands, hair follicles, epidermal 
thickness and fatty layer distribution (Fig. 3 A-C). In 
the case of the skin cancer control group, there was 
disruption of the fatty layer, an increase in epidermal 
thickness and presence of keratin pearls, rete ridges 
extending through the connective tissue, dysplastic, 
and hyperplastic epithelial cells (Fig. 3D). Treatment 
with 5-FU showed decreased rete ridges, absence of 
dysplastic epithelial cells, and unscathed fatty layer 
with the reduced epidermal thickness (Fig. 3E). 
Histopathological sections of skin from mice treated 
with 5% SLC also showed a complete absence of 
Table 2 — Effect of SLC on non-specific serum markers 
and tissue markers 
Parameters CON COF COS5 SCC SCF SCS5 






































































































































[Values represent  Mean ± SEM  of  6 mice. Significantly different from 
*Normal control group; and 
#
skin cancer control group (P <0.05). 
CON, Normal control; COF, Control treated with 2% 5-Flurouracil; 
COS5, Control treated with 5% SLC; SCC, Skin cancer control 
group; SCF, Skin cancer treated with 2% 5-Flurouracil; and SCS5, 
Skin cancer treated with 5% SLC] 
 




keratin pearls, dysplastic epithelial cells, and rete 
ridges with a decrease in epidermal thickness and 
undisrupted fatty layer; although an increased number 
of hyperplastic cells was observed (Fig. 3F).  
 
Docking study 
The docking score of SDG with CDK4 was 7.80 
while that of its standards purvanalol, roscovitine, and 
staurosporine was 7.41, 7.80, and 4.53 respectively  
(Fig. 4A). purvanalol, roscovutine, and staurosporine 
showed respectively 2, 3, and 2 hydrogen bonding 
while SDG showed 5 hydrogen bonding with the 
proteins (Table 3). Amongst several binding pockets, 
SDG exhibited hydrogen bonding with B/ARG62 and 
B/ARG/163 which are common binding sites for 
staurosporine and roscovutine respectively (Fig. 4 A,-D).  
 
mRNA expression of CDK4 and p53 
Skin cancer control group exhibited a significant 
increase in CDK4 mRNA and  a  significant  decrease  




No. of  
hydrogen bonds Binding sites 
Purvanalol 7.41 2 
1. A/GLU81 
2. A/LEU83 
















in p53 mRNA levels as compared to the normal 
control group. Treatment with 5% SLC significantly 
reduced CDK4 mRNA and significantly increased  
the p53 mRNA levels in disease-treated groups as 
compared to the skin cancer control group (Fig. 5).  
 
 
Fig. 3 — Representative image of skin tissues (40X magnification) from (A) Normal control; (B) Control animals treated with 2% 5-FU 
solution; (C) Control animals treated with 5% suspension of SLC; (D) Skin cancer control; (E) Skin cancer treated with 2% 5-FU 




Fig. 4 — Docking of (A) purvanalol; (B) roscovutine; (C) staurosporine; and (D) SDG on CDK4 protein 
 






Fig. 5 — Effect of SLC on (A) CDK4 mRNA levels; and (B) p53 
mRNA levels. [Each bar represents Mean ± S.E.M of six rats, 
Significantly different from *Normal control group (P  <0.05), 
and # skin cancer control group (P <0.05), CON, Normal control; 
SCC, Skin cancer control group; SCF, Skin cancer treated with 
2% 5-Flurouracil; SCS2, Skin cancer treated with 2% SLC; and 
SCS5, Skin cancer treated with 5% SLC] 
 
Discussion 
A-375 cells lines have characteristic features of 
growing tumors at subcutaneous region which are of 
amelanotic melanomas type
22
. In the present study, 
the IC50 value of SLC and 5-FU was 93.7 and  
89.9 µg/mL, respectively. The IC50 value of SLC 
being close to that of 5-FU indicates that SLC exhibits 
potent chemoprotective actions in skin cancer. 
DMBA and croton oil induced skin cancer model is 
a two-stage chemical method that produces skin 
papillomas at first, which are further transformed into 
deep squamous cell carcinoma in the span of  
16 weeks
23
. In the present investigation, there was a 
significant increase in tumor volume and burden in 





week which was reduced by treatment with 2% 5-FU 
and 5% SLC. Histopathology studies of the skin tissue 
also support the data of the chemoprotective role of 
SLC. Histopathological sections from the 5% SLC 
treated group showed a complete absence of keratin 
pearls, dysplastic epithelial cells, and rete ridges. 
These results suggest the chemoprotective role of 
SLC of L. usitatissimum. 
 
Higher levels of GGT, a non-specific tumor 
marker, indicate the appearance of a more aggressive 
and resistant tumor
24
. For accelerated growth of tumor 
cells, a constant amount of nutrient flow is required 
which is accomplished by an excessive supply of 
cysteine
25
. In support to supply more cysteine 
molecules into the cells, there is increased activity of 
GGT
25
. It is also reported that the application of 
DMBA and croton oil causes an increase in GGT 
levels
26
. In the present study, GGT levels were 
reduced by 5% SLC treatment. An increase in GGT 
levels is directly linked with an increase in the Ras 
pathway which is increased in skin cancer
27
. Ras 
signaling has been reported to down-regulate the 
CDK inhibition and helps in cell cycle progression
27
. 
It has been reported that lignans inhibit the CDK 
molecules either by increasing the levels of p21 or 
p16 (CDK inhibitory proteins)
9
. Thus, it can be 
proposed that incongruence to other lignans, SLC 
might have inhibited CDK which might have altered 
the Ras pathway and thereby reduced the levels of 
GGT. 
 
In the case of cancer cells, there is an increased 
formation of pyruvate in glycolysis, the level of LDH 
also increases
28
. In the present study, there was a 
decrease in levels of LDH 5% SLC treatment. It has 
been observed that with an increase in expression of 
CDK and cyclin there is an increase in levels of 
LDH
29
. Hence, SLC might inhibit the levels of CDK 
which might reduce the levels of LDH. 
An increased level of CRP is associated with an 
increased risk of cancer in a healthy individual
30
. In 
the current study, treatment with 5% SLC decreased 
CRP levels. CRP is shown to increase the levels of 
p53, and subsequently increase the levels of p21 and 
induce cell arrest
31
. Hence, a decrease in CRP levels 
by SLC suggest that through the restoration of p53, 
SLC might prevent inflammation of the tumor 
environment. Increase in non-specific markers are due 
to formation of tumors as host-tumor interaction 
occurs during cancer. In current study, SLC reduced 
tumor formation and thereby it might have altered the 
host-tumor interaction and thereby reduced the 
markers, although they have been applied locally. 




In cancer, reactive oxygen species have been 
shown to have an important role in the cancer 
development phase. With application of DMBA and 
croton oil there is increase in lipid peroxidation levels 
and decrease in GSH and SOD activity
32
. In the 
current investigation, 5% SLC controlled oxidative 
stress. Lignans, including SLC, are potent 
antioxidants
33
 that might act directly against the 
radicals. From the ongoing discussion, it appears that 
SLC controls oxidative stress and thus might serve to 
exhibit a chemoprotective role. 
 
Collagen levels, in cancer induced by DMBA and 
croton oil application, have been seen to increase in 
comparison to the normal skin. In the current study, 
there was an increase in collagen levels in the skin 
cancer control group which was reduced by 5% SLC 
treatment. An increase in TNF-α is reported to elevate 
the expression of matrix metalloproteinases(MMP), 
which further supports the spread of cancer cells
34
. 
CDK inhibition has been reported to inhibit TNF-α 
induced expression of MMP
35
. In conjunction with the 
CDK inhibitory property of lignans, there can be 
reduced levels of TNF-α which reduces the level of 
MMP expression. Due to lower levels of MMP, there 
might be a reduction in the degradation of collagen 
fibers by SLC treatment. 
 
To determine the mechanism behind the 
chemoprevention we carried out the docking studies. 
Various lignans have been reported in inhibiting the 
levels of CDK4
36
. Hence, we carried out the docking 
of SDG on CDK4 protein and compared the results 
with the docking of standards viz. roscovutine, 
staurosporine, and purvanalol B on CDK4. Data 
revealed that the binding affinity of SDG is similar to 
the binding score of roscovutine, while in comparison 
to staurosporine, and purvanalol B the docking score 
of SDG was higher. Also, the interaction between 
SDG and CDK4 molecule produced 5 hydrogen 
bonds, which were higher in comparison to the 
interaction between standards with CDK4. Hence, it 
can be proposed that the binding affinity of the  
SDG is more in comparison to purvanalol and 
staurosporine. Amongst many binding pockets found 
in SDG, binding sites like B/ARG62 and B/GLY160 
were seen to be common binding sites of 
staurosporine and roscovutine respectively. The 
similarity in binding interaction of SDG and 
staurosporine i.e. B/ARG62 is due to the presence of 
lone pair of electrons on oxygen atoms in both the 
ligands. The interaction with the B/GLY160 is due to 
the presence of the hydrogen atom in roscuvutine as 
well as in SDG. It has been shown that ATP binding 
pocket in all types of kinases is considered to be the 
conserved region
37
. This suggests that SDG interacts 
with the conserved region of the CDK4. 
 
Considering the docking studies which depicted 
that SDG might act through CDK4, we carried out 
mRNA expression studies of CDK4 from the skin 
tissue to confirm its mechanism of action. In the 
present study, the skin cancer control group showed 
increased levels of CDK4 mRNA expression which 
was reduced by treatment with 5% SLC. Raised levels 
of CDK4 along with the decreased levels of p53 
indicate the accelerated cell cycle. It has been 
reported that there is an increase in expression of 
specifically CDK4 in cancer cells
38
. Thus, this 
confirms that SLC inhibits CDK4 expression in skin 
cancer and thereby interrupts the cell cycle and 
heralds the accelerated cell growth. 
 
It has been reported that there is a decrease in 
mRNA expression of p53 in skin cancer
39
. Moreover, 
an increase in the level of p53 causes CDK inhibition 
via p21 CDK inhibitory proteins
40
. Hence, to 
corroborate the data of mechanism of action of SLC, 
we also studied the mRNA expression of p53 from 
skin tissue which revealed a decreased level of p53 in 
skin cancer control animals. 5% SLC treatment 
exhibited an increase in the level of p53. These results 
confirm that SLC increases mRNA expression of  
p53 along with decreasing the mRNA expression  
of CDK4. 
 
Despite having carried out a detailed study, this 
study holds some limitations. We were unable to carry 
out a cell cycle study using flow cytometry and could 
not determine the entire downstream pathway through 
which the drug acts. Nevertheless, future studies 
could be directed towards the determination of a 
detailed mechanism of action. This can then be taken 
to next level for isolation of SDG and designing novel 
scaffolds that are safe and more potent. 
 
Conclusion 
SLC of Linum usitatissimum (L.) exhibited a 
chemopreventive effect as depicted through reduction 
in tumor volume, tumor burden, serum and tissue 
markers. The docking and mRNA expression studies 
indicate the possible mechanism of action could be 
through the inhibition of CDK4 and upregulation  
of p53. 
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